News - Cipla, Pharmaceutical

Filter

Current filters:

CiplaPharmaceutical

Popular Filters

Indian govt to penalize drugmakers for overcharging

Indian govt to penalize drugmakers for overcharging

06-05-2014

In a major crackdown, India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA)…

CiplaFinancialGlaxoSmithKlineIndiaPharmaceuticalPricing

Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir

21-02-2014

US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

Report: Indian pharma companies’ innovation is increasing but fails to match Europe

10-01-2014

Innovation by Indian pharmaceutical companies has increased over the last few years but has not demonstrated…

CiplaDr Reddy's LaboratoriesIndiaPatentsPharmaceuticalResearch

Meda expands collaboration with India's Cipla on Dymista

06-06-2013

Swedish drugmaker Meda (OMX: MEDA A) is broadening its collaboration with Indian pharmaceutical company…

Asia-PacificCiplaDymistaLicensingMedaPharmaceuticalRespiratory and PulmonaryRest of the WorldSouth America

Indian IPAB provides relief for Pfizer in Sutent patent revocation case

05-06-2013

India's Intellectual Property Appellate Board (IPAB) has provided global pharma behemoth Pfizer (NYSE:…

Asia-PacificCiplaPatentsPfizerPharmaceuticalSutent

India's Cipla ups bid for Cipla Medpro now seeking 100% control for around $512 million

01-03-2013

Indian drugmaker Cipla (BSE: 500087) has made an offer to the shareholders of Cipla Medpro South Africa…

CiplaCipla MedproGenericsMarkets & MarketingPharmaceutical

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

10-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination

24-07-2012

Coinciding with the XIX International AIDS Conference in Washington DC, the Drugs for Neglected Diseases…

Anti-viralsCiplaGenericsGlobalPharmaceuticalResearch

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Speculation Takeda is looking to buy India’s Cipla or Lupin; Sanofi acquires OTC firm

25-08-2011

Japan’s largest drugmaker Takeda Pharmaceuticals (TYO: 4502) is in talks with two of India’s…

Asia-PacificCiplaLupinMergers & AcquisitionsPharmaceuticalSanofiTakeda PharmaceuticalsUniversal Medicare

Back to top